Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC_ [360p]
